4-Acetylamino-n-(2'-aminophenyl)benzamide
| Title | Journal |
|---|---|
| Inhibition of histone deacetylase 3 protects beta cells from cytokine-induced apoptosis. | Chemistry & biology 20120622 |
| Combined inhibition of DNA methyltransferase and histone deacetylase restores caspase-8 expression and sensitizes SCLC cells to TRAIL. | Carcinogenesis 20111001 |
| Interpreting clinical assays for histone deacetylase inhibitors. | Cancer management and research 20110101 |
| Inside HDAC with HDAC inhibitors. | European journal of medicinal chemistry 20100601 |
| Chemical phylogenetics of histone deacetylases. | Nature chemical biology 20100301 |
| A novel histone deacetylase inhibitor Chidamide induces apoptosis of human colon cancer cells. | Biochemical and biophysical research communications 20100205 |
| New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer. | Journal of hematology & oncology 20090101 |
| The potential role of histone deacetylase inhibitors in the treatment of non-small-cell lung cancer. | Critical reviews in oncology/hematology 20081001 |
| Design, synthesis, and evaluation of novel mutual prodrugs (hybrid drugs) of all-trans-retinoic acid and histone deacetylase inhibitors with enhanced anticancer activities in breast and prostate cancer cells in vitro. | Journal of medicinal chemistry 20080710 |
| CI-994 (N-acetyl-dinaline) in combination with conventional anti-cancer agents is effective against acute myeloid leukemia in vitro and in vivo. | Oncology reports 20080601 |
| Epigenetic treatment of myelodysplastic syndromes and acute myeloid leukemias. | Current medicinal chemistry 20080601 |
| Improved synthesis of histone deacetylase inhibitors (HDIs) (MS-275 and CI-994) and inhibitory effects of HDIs alone or in combination with RAMBAs or retinoids on growth of human LNCaP prostate cancer cells and tumor xenografts. | Bioorganic & medicinal chemistry 20080315 |
| Exploration of the internal cavity of histone deacetylase (HDAC) with selective HDAC1/HDAC2 inhibitors (SHI-1:2). | Bioorganic & medicinal chemistry letters 20080201 |
| Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity. | Journal of medicinal chemistry 20071115 |
| Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: results of a phase II randomized, double-blind, placebo-controlled, multicenter study. | Annals of oncology : official journal of the European Society for Medical Oncology 20060701 |
| In vitro study of CI-994, a histone deacetylase inhibitor, in non-small cell lung cancer cell lines. | Oncology research 20050101 |
| A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine. | Annals of oncology : official journal of the European Society for Medical Oncology 20041101 |
| Modulation of histone acetylation by [4-(acetylamino)-N-(2-amino-phenyl) benzamide] in HCT-8 colon carcinoma. | Molecular cancer therapeutics 20030401 |
| Phase I study of oral CI-994 in combination with gemcitabine in treatment of patients with advanced cancer. | Cancer journal (Sudbury, Mass.) 20030101 |
| Latent hematopoietic stem cell toxicity associated with protracted drug administration. | Experimental hematology 20010301 |
| Preclinical antitumor activity of CI-994. | Investigational new drugs 19960101 |